A program designed to accelerate early-stage drug discovery platforms to advanced lead and clinical candidate levels within two years, focusing on therapeutic areas like oncology, inflammation, CNS, and infectious diseases.

A collaborative platform supported by AI and computer-aided drug design, aimed at developing novel targeted treatments for cancer, immunological, and neurodegenerative diseases.